CIK 0001680581
- Non-accelerated filer
- Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474839948
- Phone
- +1 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-07-22 | Third Rock Ventures III, L.P. 10% owner | Conversion · Series A Preferred Stock | −39,166,667 | 0 | ||
| 2019-07-22 | Third Rock Ventures III, L.P. 10% owner | Conversion · Series A Preferred Stock | −0 | 0 | ||
| 2019-07-18 | Wallace Owen B. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +44,493 | 44,493 | ||
| 2019-07-18 | Collins James J. Director | Grant or award · Stock Option (right to buy) | +5,714 | 5,714 | ||
| 2019-07-18 | GERAGHTY JAMES A Director | Grant or award · Stock Option (right to buy) | +9,285 | 9,285 | ||
| 2019-07-18 | Ezekowitz Alan Director | Grant or award · Stock Option (right to buy) | +5,714 | 5,714 | ||
| 2019-07-18 | Haviland Kate Director | Grant or award · Stock Option (right to buy) | +9,285 | 9,285 | ||
| 2019-07-18 | Gould Robert J | Grant or award · Stock Option (right to buy) | +107,142 | 107,142 | ||
| 2019-07-18 | Cadavid Diego | Grant or award · Stock Option (right to buy) | +12,784 | 12,784 | ||
| 2019-07-18 | Stuart Bryan Chief Operating Officer | Grant or award · Stock Option (right to buy) | +28,571 | 28,571 | ||
| 2019-07-18 | Thomson Peter G. | Grant or award · Stock Option (right to buy) | +7,078 | 7,078 |
Page 15 of 15 · 291 trades